Drugs / LY03003
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04630860 | Jul 2020 → May 2021 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04384666 | Jun → Aug 2020 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03733561 | Nov → Dec 2018 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04629404 | Nov 2018 → Mar 2019 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03589066 | May → Oct 2018 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04045678 | Oct 2017 → Apr 2019 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02055274 | Oct 2013 → Aug 2015 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04571164 | May 2020 → Mar 2022 | Parkinson disease | Luye Pharma Group Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY03003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04045678 ↗ |
| Known as | Rotigotine | “LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)” NCT03733561 ↗4“LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)” NCT04384666 ↗ “LY03003 ( Rotigotine, extended-release microspheres)” NCT04045678 ↗ “LY03003(Rotigotine,extended-release microspheres)” NCT04571164 ↗ “Rotigotine,extended-release microspheres” NCT04630860 ↗ |
| Route | Intramuscular | “Following Intramuscular Injections” NCT02055274 ↗ |